SCHEMBL13087281

SCHEMBL13087281

N#Cc1cccc(-c2cc(OC3CN(C(=O)c4ccnnc4)C3)c3cnccc3c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.39
PDE10A Q9Y233 1/20 0.37
TTK P33981 1/20 0.36
SMO Q99835 1/20 0.35
BRD4 O60885 1/20 0.35
BRD2 P25440 1/20 0.35
NAMPT P43490 1/20 0.35
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
DGAT2 Q96PD7 1/20 0.35
PAX8 Q06710 1/20 0.35
SLC22A12 Q96S37 1/20 0.34
USP30 Q70CQ3 1/20 0.34
IKBKB O14920 1/20 0.34
CHUK O15111 1/20 0.34
GRM5 P41594 2/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA5 P30532 1/20 0.33
CHRNA4 P43681 1/20 0.33
HCRTR1 O43613 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087328 0.92 SLC6A7 (0.42) SLC6A7SMONAMPTIKBKBCHUK
SCHEMBL13558994 0.86 SLC6A7 (0.39) SLC6A7PDE10ATTKNAMPTCYP11B1
SCHEMBL13087168 0.86 SLC6A7 (0.39) SLC6A7PDE10ATTKNAMPTHCRTR1
SCHEMBL13087387 0.85 TBK1 (0.39) SLC6A7PDE10ANAMPTDGAT2PAX8
SCHEMBL13087394 0.84 KCNK3 (0.41) SLC6A7PDE10ACYP11B1CYP11B2DGAT2
SCHEMBL13087782 0.84 PDE10A (0.37) SLC6A7PDE10ANAMPTCYP11B2DGAT2
SCHEMBL13087388 0.84 ALDH1A1 (0.47) SLC6A7SMONAMPTCYP11B1CYP11B2
SCHEMBL2428445 0.83 CYP11B2 (0.35) CYP11B1CYP11B2DGAT2PAX8USP30
SCHEMBL13089978 0.82 KDM1A (0.38) NAMPTDGAT2PAX8SLC22A12USP30
SCHEMBL13087208 0.82 SLC22A12 (0.39) SLC6A7PDE10ANAMPTCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 SLC6A7 3166/4885PDE10A 4001/4885TTK 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.